Erbitux in combination with radiation therapy or in combination with platinum-based therapy with 5-FU:
Premedicate with an H1 antagonist (eg, 50 mg of diphenhydramine) intravenously 30â€“60 minutes prior to the first dose; premedication should be administered for subsequent Erbitux doses based upon clinical judgment and presence/severity of prior infusion reactions.
Reduce the infusion rate by 50% for NCI CTC Grade 1 or 2 and non-serious NCI CTC Grade 3 infusion reaction.
Immediately and permanently discontinue Erbitux for serious infusion reactions, requiring medical intervention and/or hospitalization. [See WARNINGS AND PRECAUTIONS]
Recommended dose modifications for severe (NCI CTC Grade 3 or 4) acneiform rash are specified in Table 1. [See WARNINGS AND PRECAUTIONS]
Table 1: Erbitux Dose Modification Guidelines for Rash 
Do not administer Erbitux as an intravenous push or bolus. 
Administer via infusion pump or syringe pump. Do not exceed an infusion rate of 10 mg/min.
Administer through a low protein binding 0.22-micrometer in-line filter. 
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
The solution should be clear and colorless and may contain a small amount of easily visible, white, amorphous, cetuximab particulates. Do not shake or dilute.
